SLEEP · 2005 · 52 citations · 16 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyNeuropharmacologySleep MedicineSleep AssessmentSleep Disorder PharmacotherapySleep Disturbances In Older AdultsSleep HealthSleep ManagementDose ResponseDose Response EffectsNighttime AwakeningsPolysomnography AnalysisSleep ContinuitySleep Medication SafetySleep TimeSlow-wave Activity
STUDY OBJECTIVES: To evaluate the dose- response effects of tiagabine on sleep and safety measures in healthy older adults. DESIGN: Randomized, double-blind, Latin-square design. SETTING: Sleep laboratory. PARTICIPANTS: Twenty-four healthy older adults (11 men, 13 women; mean age 68.0 +/- 6.2 years) INTERVENTIONS: Tiagabine 2, 4, or 8 mg, or placebo, each given on two consecutive nights. MEASUREMENTS AND RESULTS: Polysomnography revealed that compared with placebo, tiagabine 4 mg increased total sleep time, reduced wake after sleep onset, and increased minutes of slow-wave sleep. Tiagabine 8 mg decreased wake after sleep onset, increased slow-wave sleep, and improved a sleep-continuity index. No differences were seen between the 2-mg dose and placebo. Subjective ratings indicated fewer awakenings with the 8-mg dose. Central nervous system adverse events were somewhat higher in the 8-mg condition only. Measures of morning performance were minimally affected. CONCLUSIONS: Research with tiagabine at dosages of 8 mg or less appears warranted in elderly clinical populations.
16
A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
Martin B. Scharf, Thomas Röth, Gerald W. Vogel et al. · PubMed · 1994 · 223 citations